COVID-19 treatment: Good News! CSIR CDRI Lucknow gets approval for trial of drug Umifenovir

By: |
Published: June 18, 2020 7:23 PM

Council of Scientific and Industrial Research (CSIR) constituent lab CSIR-Central Drug Research Institute (CDRI), Lucknow has received permission for carrying out Phase III randomised, trial of efficacy, safety and tolerability of antiviral drug Umifenovir.

covid 19, coronavirus update, Umifenovir The drug has a good safety profile and acts by preventing entry of virus into human cells. (File Photo for representation)

COVID-19 drug latest news: Amid an intense race to develop a vaccine or a drug against the deadly coronavirus infection, a ray of hope has emerged in India. Council of Scientific and Industrial Research (CSIR) constituent lab CSIR-Central Drug Research Institute (CDRI), Lucknow has received permission for carrying out Phase III randomised, trial of efficacy, safety and tolerability of antiviral drug Umifenovir.

According to a statement issued by the Ministry of Science and Technology, the trials will be carried out at King George’s Medical University (KGMU), Dr. Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and ERA’s Lucknow Medical College and Hospital, Lucknow.

“This drug has a good safety profile and acts by preventing entry of virus into human cells and also by priming the immune system. Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid19 patients,” the statement said.

All the raw material for Umifenovir are indigenously available and if the clinical trial is successful, Professor Tapas Kundu, Director CSIR-CDRI said. Umifenovir can be a safe, efficacious, affordable drug against COVID-19 and can be part of National Program against COVID-19, he added.

Scientists across the world are involved in massive effort to develop a vaccine against the COVID-19 infection which has affected over 83 lakh people and killed more than 4 lakh. In India, over 3.66 lakh people have been infected, and the death toll stands at over 12,000.

Meanwhile, tests have shown that low doses of dexamethasone can reduce deaths of one-third patients affected by COVID-19. The researchers arrived at the conclusion after assessing the inexpensive drug on 2,100 people, news agency PTI reported.

The research on low-dose dexamethasone steroid treatment was a part of the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial that was testing the efficacy of a wide-range of drugs and therapies for COVID-19, the report said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Tracking Covid-19: Testing helps reduce fatalities
2Corona cases surge in Pune, Pimpri Chinchwad, 10-day lockdown to be imposed from Monday
3India’s COVID-19 tally crosses 8-lakh mark, recovery rate rises further to 62.42 per cent